ARCHIVES

FDA Plans to Discuss the Negative Trial of AstraZeneca’s Drug Iressa With the Oncologic Drugs Advisory Committee in March.

This article is from The Cancer Letter archive.

Vol. 31 No. 03 | January 21, 2005

Download PDF Visit The Full Archive

Related Articles

NCI Advisory Group, Other Cancer Meetings

February 24, 1984

Implantable Drug Delivery Device Offers Better Pain Relief

September 27, 2002

NCI RFAs Available

May 5, 2000

ACS-Roosevelt Fellows Announced

July 29, 1977

Hammer to Produce US-USSR “Cancer Summit” March 29

March 25, 1988

ODAC Finds Increase In Progression-Free Survival Unconvincing To Approve sNDA For Gemzar In Advanced Ovarian Cancer.

March 24, 2006